Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon

News provided by

Sep 09, 2024, 07:00 ET

DALLAS, Sept. 9, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced presentations at the Retina Society 57^th Annual Scientific Meeting and at Advanced Therapies Europe taking place during the 2^nd week of September in Lisbon, Portugal. Details for the presentations are as follows:

Title: BCVA Analysis of Patients Treated with Low- or High-Dose MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 100-week TOPLINE Results from a Phase 2b/3 Randomized, Sham-Controlled Clinical Trial (RESTORE)
Session Title: Genetic Diseases, Dystrophies & Degenerations
Session Date: September 11, 2024
Session Time: 4:25 p.m. WEST
Location: Pedro Leitao Ballroom, Four Seasons Hotel Ritz, Lisbon
Presenter: Anat Loewenstein, MD, MHA, Professor and Director, Division of Ophthalmol., Tel Aviv University

In her presentation, Dr. Loewenstein will highlight the end-of-study 100 week RESTORE data from mutation-agnostic Multi-Characteristic Opsin (MCO) therapy of severe vision loss due to retinitis pigmentosa.

Title: Democratizing Gene Therapy for Neurodegenerative Diseases
Session Title: Gene Therapy: Spotlight on Developments and Breakthroughs
Session Date: September 11, 2024
Session Time: 4:15 p.m. WEST
Location: Estoril Convention Center, Lisbon
Presenter: Samarendra Mohanty, PhD, President & Chief Scientific Officer

During his presentation, Dr. Mohanty will highlight the recent developments and breakthroughs on mutation-agnostic optogenetic gene therapy for vision restoration in inherited retinal dystrophies, and image-guided spatially targeted laser gene delivery platform for treating geographic atrophy. The presentation will be followed by a panel discussion at 4:45 pm. Dr. Mohanty will also chair a session titled "Flexibility in Action: Harnessing Adaptive Vector Platforms for Gene Therapy Manufacturing" on September 12, 2024, from 1:45 - 3: 00 p.m. WEST.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company's lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
(212) 600-1902
[email protected]

SOURCE Nanoscope Therapeutics